Respiratory syncytial virus G protein

Insights into the Global Respiratory Syncytial Virus Therapeutics Market (2018 to 2026) - Featuring AstraZeneca, AbbVie & F. Hoffmann-La Roche Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, March 30, 2020
Health, Pharmaceutical, Human orthopneumovirus, Paramyxoviridae, Viruses, RSV, Mononegavirales, AstraZeneca, Respiratory syncytial virus G protein, Orthopneumovirus

The "Global Respiratory Syncytial Virus Therapeutics Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Respiratory Syncytial Virus Therapeutics Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.
  • The Respiratory Syncytial Virus Therapeutics market is expected to reach $2,958.92 million by 2026 growing at a CAGR of 13.4% from 2018 to 2026.
  • Respiratory syncytial virus (RSV) is a common and contagious virus that infects the respiratory tract of children and adults.
  • No specific approved drug or vaccine has been available to treat or prevent RSV infection to date.

New Research Examines Key Players Involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) Targeted Therapeutics Markets and Key Projects

Retrieved on: 
Wednesday, October 9, 2019
Branches of biology, Respiratory syncytial virus G protein, RSV, Human orthopneumovirus, Syncytium, Biology, Mononegavirales

DUBLIN, Oct. 9, 2019 /PRNewswire/ -- The "Respiratory Syncytial Virus Attachment Glycoprotein - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 9, 2019 /PRNewswire/ -- The "Respiratory Syncytial Virus Attachment Glycoprotein - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report Respiratory Syncytial Virus Attachment Glycoprotein - Pipeline Review, H2 2019, outlays comprehensive information on the Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Respiratory syncytial virus G protein is a protein produced by respiratory syncytial virus.
  • Furthermore, this report also reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics development with respective active and dormant or discontinued projects.

Respiratory Syncytial Virus Attachment Glycoprotein - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 9, 2019
Biotechnology, Medical devices, Health, Pharmaceutical, Branches of biology, Respiratory syncytial virus G protein, RSV, Human orthopneumovirus, Syncytium, Biology, Mononegavirales

The "Respiratory Syncytial Virus Attachment Glycoprotein - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Respiratory Syncytial Virus Attachment Glycoprotein - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report Respiratory Syncytial Virus Attachment Glycoprotein - Pipeline Review, H2 2019, outlays comprehensive information on the Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Respiratory syncytial virus G protein is a protein produced by respiratory syncytial virus.
  • Furthermore, this report also reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics development with respective active and dormant or discontinued projects.